Raptiva Genentech Inc. - Treatment for Psoriasis
Raptiva is the first biologic therapy that is designed to provide
continuous control of chronic moderate-to-severe plaque psoriasis
and can be self-administered by patients as a single, once-weekly,
subcutaneous injection. Raptiva has been approved for the treatment
of chronic moderate-to-severe plaque psoriasis in adults age 18 or
older who are candidates for systemic therapy or phototherapy.
Posted: October 2003